Filipczak- Bryniarska I. (2017, Poland)

[23]

Unicentric trial, single-arm

18

High-dose 8% Capsaicin patch

Painful peripheral polyneuropathy (clinical history and neurological examination by a neurologist), with NRS ≥4

Colon cancer, submit to oxaliplatin-based ChT

NRS at baseline and on 1 and 8 days after, and 8 and 12 weeks after

Reduction of NRS score occurred in

84% - 97% of pts, after 12 weeks.

None of the adverse events occurred.

13

1, 2, 4, 5, 6, 9, 10, 13, 14, 16, 17, 18, 19

Barton D. L. (2011, USA)

[27]

Multicentric, randomized, double-blind, placebo-controlled trial

208

Topical BAK gel (baclofen 0.8%, amitriptyline 3% and ketamine 1.5%), bid, for 4 weeks

>1 month symptomatic CIPN, with numbness, tingling or pain level of ≥4 out of 10

Any cancer and stage. Active or previous treatment with neurotoxic ChT

Sensory subscale of the EORTC QLQ-CIPN20, at baseline and 4 weeks after

A greater improvement for BAK arm (vs. placebo) in the sensory subscale (p = 0.053).

Without undesirable toxicities.

No evidence of systemic toxicity.

12

1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 16, 19

Gewandter J. S. (2014, USA)

[28]

Multicentric, phase III randomized, double-blind, placebo-controlledtrial

462

Topical KA cream (ketamine 2% and amitriptyline 4%), bid, for 6 weeks

CIPN (pain, numbness, and tingling) ≥ 4 out of 10; ≥1 month beyond ChT completion

Any cancer and stage. Previous treatment with neurotoxic ChT (taxane vs. non-taxane)

Pain, numbness, and tingling scoresat baseline and at 6 weeks after

No effect on 6-week CIPN scores (p = 0.363).

Adverse events occurred at relatively equivalent rates and severity in both arms.

11

2, 3, 4, 5, 6, 7, 8, 9, 13, 16, 18

Rossignol J. (2019, France)

[24]

Unicentric trial, single-arm, pilot study

44

Topical 10% Amitriptyline cream bid

CIPN with NCI-CTCAE v4.0 grade >1

Haematological or solid tumours. Previous treatment with neurotoxic ChT

VAS on the baseline; and at 1, 2 and 4 weeks; and then monthly up to 1 year

Median VAS score decreased from 7 (4 - 9) to 2 (0 - 4) after 4-week treatment

Discontinuation is only 1 patient (skin irritation)

11

2, 3, 4, 5, 6, 9, 13, 16, 17, 18, 19

Prinsloo S. (2017, USA)

[22]

Unicentric, randomized, waitlist-controlled trial, pilot study

62

Neurofeedback: 20 sessions (twice a week)

CIPN with NCI-CTCAE v4.0 grade ≥3 and/or neuropathic pain (NRS ≥4), for ≥3 months beyond ChT completion

Any cancer and stage. Previous treatment with neurotoxic ChT

BPI-SF worst-pain item, on the baseline and then weekly until the end

Decrease in BPI-SF worst pain (mean change score: −2.43 vs. 0,09, p = 0.001)

All pts completed NFB treatment, without discontinuation problem or side effects

13

1, 2, 3, 4, 5, 7, 9, 12, 13, 16, 17, 18, 19